<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Nodule Management

We help solve complex diagnostic challenges in lung nodule management and diagnosis.

Leading pulmonologists continue to advance nodule management programs to screen and evaluate patients. However, with 95% of nodules found incidentally, many challenges remain.

More than 1.6 million nodules are detected incidentally each year in the US1, but only 1 in 3 patients ever receive a follow-up clinical evaluation2.

Clinical risk assessment has become a critical component of managing patients with newly discovered nodules.  When less than 5% of pulmonary nodules are diagnosed as lung cancer1,2, physicians must weigh the benefit of avoiding invasive procedures and the risk of delayed intervention.  

An estimated 3/4 of patients are characterized with low to moderate risk nodules, for which there is no standard approach for physicians to determine the next step for the patient's care. As a result, it takes on average 8 months for a nodule to be diagnosed as either malignant or benign2.

To assess a patient's nodule, use the Solitary Pulmonary Nodule Malignancy Risk Calculator (Mayo Model)3.


The Nodify XL2™ blood test helps direct next steps in lung nodule management

Physicians share their experiences with Nodify XL2 testing and how it helps them manage their lung nodule patients and helps avoid unnecessary procedures


Rule out malignancy prior to bronchoscopy with Nodify XL2™ testing.

Designed to help physicians identify likely benign lung nodules using a simple to use blood-based test for patients with low to moderate risk incidental lung nodules.

Learn more about Nodify XL2™

  1. Gould et al, "Recent Trends in the Identification of Incidental Pulmonary Nodules," American Journal of Respiratory and Critical Care Medicine, vol. 192, no. 10, 2015.
  2. Pyenson et al, “No Apparent Workup for most new Indeterminate Pulmonary Nodules in US Commercially-Insured Patients.” Journal of Health Economics and Outcomes Research. 2019; 6(3): 118-29.
  1. Swensen SJ, Silverstein MD, Ilstrup DM, et. al. "The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules," Arch Intern Med 1997 Apr 28; 157(8):849-55.
  2. Tanner et al. "Management of Pulmonary Nodules by Community Pulmonologists. A Multicenter Observational Study," Chest, vol. 148, no. 6, pp. 1405-1414, 2015.